Initiates Coverage on Pulmatrix (NASDAQ:PULM) assumed coverage on shares of Pulmatrix (NASDAQ:PULMGet Rating) in a research report released on Monday. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix Stock Down 1.1 %

Shares of NASDAQ:PULM opened at $4.40 on Monday. Pulmatrix has a 1-year low of $4.03 and a 1-year high of $20.80. The firm’s 50 day simple moving average is $4.69 and its two-hundred day simple moving average is $5.90.

Pulmatrix (NASDAQ:PULMGet Rating) last released its earnings results on Thursday, May 12th. The biotechnology company reported ($1.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.10). Pulmatrix had a negative net margin of 426.00% and a negative return on equity of 37.38%. The firm had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.07 million. On average, sell-side analysts anticipate that Pulmatrix will post -6.04 EPS for the current fiscal year.

Institutional Trading of Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. Murchinson Ltd. acquired a new stake in shares of Pulmatrix, Inc. (NASDAQ:PULMGet Rating) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 100,000 shares of the biotechnology company’s stock, valued at approximately $44,000. Murchinson Ltd. owned approximately 0.18% of Pulmatrix at the end of the most recent reporting period.

Pulmatrix Company Profile

(Get Rating)

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with's FREE daily email newsletter.